# Study to Compare the Pharmacokinetics and Pharmacodynamics of ASA Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary Function

> **NCT05625347** · PHASE1 · TERMINATED · sponsor: **Vectura, Inc.** · enrollment: 4 (actual)

## Conditions studied

- Obstructive Pulmonary Function
- Restrictive Pulmonary Function

## Interventions

- **DRUG:** single dose (100 mg) of ASA
- **DRUG:** single dose (162 mg) of non-enteric-coated chewable aspirin tablets

## Key facts

- **NCT ID:** NCT05625347
- **Lead sponsor:** Vectura, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-03-11
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** The pivotal study failed to meet the primary endpoint. Without a successful readout of the pivotal study, there was no longer a purpose for the supportive BORA-1A-C302 study.
- **Last updated:** 2024-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05625347

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05625347, "Study to Compare the Pharmacokinetics and Pharmacodynamics of ASA Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary Function". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05625347. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*